Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

observed in the eight patients who received blinatumomab and then underwent a transplant. This highlights the potential for blinatumomab to provide an opportunity to arrange a transplant, and potentially to improve the outcome of the transplant by safely reducing the burden of leukemia before transplant."

"These data continue to validate our confidence in blinatumomab's potential as a promising new treatment option for patients with ALL and heighten our excitement in the pivotal trial we are on track to begin in the third quarter," said Christian Itin, Ph.D, Micromet's President and Chief Executive Officer.  

Pivotal Trial in ALL

Based on the results reported to date in ALL, Micromet plans to initiate a pivotal, non-randomized, multi-center trial intended to confirm the efficacy and safety of blinatumomab in adult patients with B precursor ALL with minimal residual disease after treatment with front-line chemotherapy. Patients will receive 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle.  The primary endpoint of the study is MRD response as assessed by PCR analysis.  The key secondary endpoint is time to hematological relapse (for non-transplanted patients).  The Company currently plans to enroll up to 130 evaluable patients at approximately 70 leading cancer centers in Europe and the U.S.

Conference Call and Webcast

Micromet management will host a conference call on Tuesday, June 15 at 8:30 AM EDT to review the data presented at EHA. To participate in the conference call, please dial 866-770-7120 (domestic) or 617-213-8065 (international) and reference the access cod
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  EP Global ... executives have recently contacted the Company about discussing ... as early as Monday, August 3, 2015.  Novartis ... as saying that the coming electronic contact lens ... dollars over the next several years.  Novartis partnered ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
(Date:7/31/2015)... Wilmington, DE (PRWEB) , ... July 31, 2015 ... ... long term care client base, with the recent implementation of Microsoft Dynamics GP ... provider in the industry, Intellitec is now supporting senior living communities in 16 ...
(Date:7/30/2015)... ... 31, 2015 , ... When responsible for the care of an aging loved ... through your mind: What happens if mom falls? Who will remind Dad to take ... plans. , But not taking time away from caregiving responsibilities can lead to bigger ...
(Date:7/30/2015)... ... July 31, 2015 , ... On July 22nd the Bradenton Herald ... plausible solutions for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, ... perpetuating the heroin crisis in North Florida. The task force has proposed to instate ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards for ... published for use on the CDISC website . These three Therapeutic Area ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Westchester, Ill. A study in the Feb. 1 issue ... impairments in older men with obstructive sleep apnea (OSA) are ... , A modest link between OSA severity and ... longer statistically significant after controlling for total sleep time. ...
... Researchers at Stanford University School of Medicine have identified ... Blocking the expression of the protein slowed or prevented ... vulnerable to the conditions of low oxygen that occur ... inhibiting the protein inhibits the tumor,s ability to grow," ...
... radiotherapy delivery systems cut dose, side effects after rare ... The best way to treat a rare form of ... by targeted radiotherapy, U.S. researchers say. , Ependymoma affects ... but concerns about side effects have limited the use ...
... Reported; No Other Products Within the NutriSystem Food Portfolio ... NutriSystem Inc., a leading provider of weight management products ... its NutriSystem-branded Peanut Butter Granola Bar due to the ... include all peanut products manufactured from January 1, 2007 ...
... of small arteries at the surface of the brain redirects ... to tissue starved of nutrients and oxygen following a stroke, ... optimistic news," said David Kleinfeld, a physics professor at the ... in animal models of stroke. , Damage from stroke can ...
... Officials with Baylor Health Care System ... the Baylor Research Institute (BRI) as vice ... 1. (Photo: http://www.newscom.com/cgi-bin/prnh/20090130/DC65143 )Under his leadership, ... of its unique research technologies in areas ...
Cached Medicine News:Health News:Daytime impairments in older men with obstructive sleep apnea are related to total sleep time 2Health News:Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein 2Health News:Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein 3Health News:Aggressive Treatment Effective in Kids' Brain Cancer 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 3Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer 2Health News:Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: